Astrazeneca PLC Company Profile (NYSE:AZN)

About Astrazeneca PLC (NYSE:AZN)

Astrazeneca PLC logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:AZN
  • CUSIP: N/A
  • Web:
  • Market Cap: $86.97 billion
  • Outstanding Shares: 2,532,000,000
Average Prices:
  • 50 Day Moving Avg: $33.53
  • 200 Day Moving Avg: $30.13
  • 52 Week Range: $25.55 - $35.27
  • Trailing P/E Ratio: 25.73
  • Foreward P/E Ratio: 17.44
  • P/E Growth: 2.60
Sales & Book Value:
  • Annual Revenue: $22.29 billion
  • Price / Sales: 3.90
  • Book Value: $5.13 per share
  • Price / Book: 6.70
  • Annual Dividend: $1.37
  • Dividend Yield: 5.4%
  • EBIDTA: $5.84 billion
  • Net Margins: 15.21%
  • Return on Equity: 35.65%
  • Return on Assets: 8.77%
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 0.75%
  • Quick Ratio: 0.58%
  • Average Volume: 4.13 million shs.
  • Beta: 0.81
  • Short Ratio: 6.39

Frequently Asked Questions for Astrazeneca PLC (NYSE:AZN)

What is Astrazeneca PLC's stock symbol?

Astrazeneca PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does Astrazeneca PLC pay dividends? What is the dividend yield for Astrazeneca PLC?

Astrazeneca PLC declared a semiannual dividend on Friday, February 3rd. Shareholders of record on Friday, February 17th will be given a dividend of $0.95 per share on Monday, March 20th. This represents a yield of 6.81%. The ex-dividend date of this dividend is Wednesday, February 15th. View Astrazeneca PLC's Dividend History.

When did Astrazeneca PLC's stock split? How did Astrazeneca PLC's stock split work?

Astrazeneca PLC shares split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of Astrazeneca PLC stock prior to the split would have 200 shares after the split.

How were Astrazeneca PLC's earnings last quarter?

Astrazeneca PLC (NYSE:AZN) posted its earnings results on Thursday, April, 27th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.61. The business earned $5.41 billion during the quarter, compared to the consensus estimate of $5.40 billion. Astrazeneca PLC had a net margin of 15.21% and a return on equity of 35.65%. Astrazeneca PLC's quarterly revenue was down 11.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.95 EPS. View Astrazeneca PLC's Earnings History.

Where is Astrazeneca PLC's stock going? Where will Astrazeneca PLC's stock price be in 2017?

19 analysts have issued 1-year price targets for Astrazeneca PLC's shares. Their predictions range from $36.00 to $41.37. On average, they anticipate Astrazeneca PLC's share price to reach $38.46 in the next year. View Analyst Ratings for Astrazeneca PLC.

Are investors shorting Astrazeneca PLC?

Astrazeneca PLC saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 27,947,608 shares, a drop of 10.2% from the April 28th total of 31,107,207 shares. Based on an average daily trading volume, of 4,927,299 shares, the days-to-cover ratio is currently 5.7 days.

Who are some of Astrazeneca PLC's key competitors?

Who are Astrazeneca PLC's key executives?

Astrazeneca PLC's management team includes the folowing people:

  • Pascal Soriot, Executive Director and Chief Executive Officer
  • Marc Dunoyer, Executive Director, Chief Financial Officer
  • Fiona Cicconi, Executive Vice-President, Human Resources
  • Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
  • Pam P. Cheng, Executive Vice President - Operations and Information Technology
  • Ruud Dobber, Executive Vice President, North America
  • Bahija Jallal Ph.D., Executive Vice President, MedImmune
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
  • Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
  • Leon Wang, Executive Vice President - Asia Pacific

Who owns Astrazeneca PLC stock?

Astrazeneca PLC's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (0.00%), Bank of America Corp DE (1.81%), Primecap Management Co. CA (0.00%), Epoch Investment Partners Inc. (0.00%), BlackRock Inc. (0.00%) and Schafer Cullen Capital Management Inc. (0.00%). View Institutional Ownership Trends for Astrazeneca PLC.

Who sold Astrazeneca PLC stock? Who is selling Astrazeneca PLC stock?

Astrazeneca PLC's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., FMR LLC, Credit Suisse AG, Sivik Global Healthcare LLC, Sensato Investors LLC, Epoch Investment Partners Inc., Cullen Capital Management LLC and Bluestein R H & Co.. View Insider Buying and Selling for Astrazeneca PLC.

Who bought Astrazeneca PLC stock? Who is buying Astrazeneca PLC stock?

Astrazeneca PLC's stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Primecap Management Co. CA, BlackRock Inc., Wellington Management Group LLP, Acadian Asset Management LLC, Wells Fargo & Company MN, Karp Capital Management Corp and Global Financial Private Capital LLC. View Insider Buying and Selling for Astrazeneca PLC.

How do I buy Astrazeneca PLC stock?

Shares of Astrazeneca PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Astrazeneca PLC's stock price today?

One share of Astrazeneca PLC stock can currently be purchased for approximately $34.35.

MarketBeat Community Rating for Astrazeneca PLC (NYSE AZN)
Community Ranking:  1.7 out of 5 ()
Outperform Votes:  400 (Vote Outperform)
Underperform Votes:  772 (Vote Underperform)
Total Votes:  1,172
MarketBeat's community ratings are surveys of what our community members think about Astrazeneca PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Astrazeneca PLC (NYSE:AZN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.42)
Consensus Price Target: $38.46 (11.96% upside)

Analysts' Ratings History for Astrazeneca PLC (NYSE:AZN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/17/2017Leerink SwannReiterated RatingOutperform$33.00 -> $36.00LowView Rating Details
5/12/2017Credit Suisse GroupUpgradeUnderperform -> NeutralHighView Rating Details
4/10/2017Jefferies Group LLCReiterated RatingBuy -> HoldLowView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageOverweightN/AView Rating Details
3/6/2017Cowen and CompanyReiterated RatingMarket PerformN/AView Rating Details
2/21/2017Berenberg BankReiterated RatingBuyN/AView Rating Details
12/13/2016J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
11/11/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
11/11/2016Beaufort SecuritiesReiterated RatingHoldN/AView Rating Details
11/10/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
11/10/2016Bank of America CorporationReiterated RatingBuy$41.37N/AView Rating Details
11/10/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
11/7/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
10/5/2016Goldman Sachs Group, Inc. (The)Reiterated RatingSellN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
9/13/2016BNP ParibasDowngradeOutperform -> NeutralN/AView Rating Details
8/29/2016ArgusUpgradeHold -> Buy$38.00N/AView Rating Details
2/28/2016Drexel HamiltonInitiated CoverageBuyN/AView Rating Details
2/5/2016Sanford C. BernsteinLower Price Target$34.00 -> $32.00N/AView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> Top PickN/AView Rating Details
12/30/2015Morgan StanleyReiterated RatingBuyN/AView Rating Details
11/2/2015Nordea Equity ResearchDowngradeBuy -> HoldN/AView Rating Details
9/18/2015Bryan, Garnier & CoUpgradeNeutral -> BuyN/AView Rating Details
7/31/2015S&P Equity ResearchUpgradeBuy$38.00N/AView Rating Details
7/31/2015SwedbankUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 6/28/2015 forward)


Earnings History for Astrazeneca PLC (NYSE:AZN)
Earnings by Quarter for Astrazeneca PLC (NYSE:AZN)
Earnings History by Quarter for Astrazeneca PLC (NYSE AZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/20173/31/2017$0.38$0.99$5.40 billion$5.41 billionViewN/AView Earnings Details
2/2/2017Q416$0.51$1.21$5.43 billion$5.59 billionViewListenView Earnings Details
11/10/2016Q316$0.48$1.32$5.95 billion$5.70 billionViewN/AView Earnings Details
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$0.52$1.21$6.02 billion$5.84 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details
4/29/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Astrazeneca PLC (NYSE:AZN)
2017 EPS Consensus Estimate: $1.74
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.37$0.38$0.38
Q2 20171$0.42$0.42$0.42
Q3 20171$0.38$0.38$0.38
Q4 20171$0.56$0.56$0.56
(Data provided by Zacks Investment Research)


Current Dividend Information for Astrazeneca PLC (NYSE:AZN)
Most Recent Dividend:3/20/2017
Annual Dividend:$1.37
Dividend Yield:3.99%
Dividend Growth:-21.20% (3 Year Average)
Payout Ratio:51.31% (Trailing 12 Months of Earnings)
73.66% (Based on This Year's Estimates)
69.54% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Astrazeneca PLC (NYSE:AZN)

Dividend History by Quarter for Astrazeneca PLC (NYSE AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Astrazeneca PLC (NYSE:AZN)
No insider trades for this company have been tracked by


Headline Trends for Astrazeneca PLC (NYSE:AZN)
Latest Headlines for Astrazeneca PLC (NYSE:AZN)
DateHeadline logoAstraZeneca's Faslodex Recommended by CHMP for 1st Line Use - June 27 at 3:56 PM logoAstraZeneca's Faslodex Recommended by CHMP for 1st Line Use - June 27 at 3:56 PM logoFinancial Contrast: SciClone Pharmaceuticals (SCLN) & Astrazeneca PLC (AZN) - June 24 at 6:06 PM logoAstraZeneca (AZN) Presents At 2017 Wells Fargo West Coast Energy Conference - Slideshow - June 21 at 4:42 PM logo4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio - June 20 at 4:25 PM logoClovis Up Nearly 50% on Solid Data from Ovarian Cancer Study - June 20 at 4:25 PM logo5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017 - June 20 at 4:25 PM logoCould Tesaro Overcome Clovis' Lead On Combos With Merck & Co.? - June 20 at 4:25 PM logoClovis Oncology's Rubraca Notches Key Trial Win - June 19 at 3:56 PM logoCan AstraZeneca Thrive on Its Own? Big Test Looms - June 19 at 10:09 AM logoHealth Care Stocks Are Crushing the S&P 500 - June 19 at 10:09 AM logo[$$] Can AstraZeneca Thrive on Its Own? Big Test Looms - June 19 at 10:09 AM logoWhy This Cancer Drug Specialist Is Up 50% Today - June 19 at 10:09 AM logoCan AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs? - June 16 at 4:30 PM logoAstrazeneca PLC Target of Unusually Large Options Trading (AZN) - June 16 at 8:21 AM logo[$$] European takeover rules merit a sceptical response - June 15 at 5:32 PM
News IconBRIEF-Astrazeneca presents new data underpinning safety profile and real-world cv outcomes of Farxiga at ADA 2017 - June 13 at 6:15 PM logo[$$] AstraZeneca CEO warns of 'substantial setback' if new drug fails - June 13 at 6:15 PM logoAstraZeneca Presents New Data Underpinning Safety Profile and Real-World CV Outcomes of Farxiga at ADA 2017 - June 13 at 6:15 PM logoRegulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip - June 13 at 6:15 PM logoInvestors Buy High Volume of Astrazeneca PLC Put Options (AZN) - June 13 at 5:18 PM logoAstraZeneca Presents New Data On Farxiga - Nasdaq - June 12 at 4:48 PM logoAstraZeneca to Present Scientific Advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions - June 8 at 4:30 PM logoAstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan - June 8 at 4:30 PM logoAstraZeneca PLC (AZN) Presents At American Society of Clinical Oncology 2017 - Slideshow - June 8 at 2:02 AM logoAstraZeneca plc (AZN) Given Average Rating of "Hold" by Analysts - June 6 at 6:41 PM logoAstraZeneca aims to raise $2 billion in bonds - June 6 at 3:53 PM logoAstraZeneca Presents Tagrisso® (osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases - June 6 at 3:53 PM logoIncyte: Don't Worry…Be Happy! - June 6 at 3:53 PM logoDow's Merck Making Massive Strides With Keytruda, Analyst Says - June 6 at 3:53 PM logoBristol-Myers Squibb: Value Or Value Trap? - June 5 at 3:16 PM logoLYNPARZA™ (olaparib) Significantly Reduces the Risk of Disease Worsening or Death in Patients with BRCA-Mutated Metastatic Breast Cancer - June 5 at 12:58 PM logoAstraZeneca's Big Bet on Oncology May Finally Pay Off - June 5 at 12:58 PM logoInsider Q&A: Drug industry learns to listen to patients - June 4 at 3:49 PM logoOrexo Stock Up On $2.5 Mln Milestone Payment From AstraZeneca - June 2 at 5:05 PM logoStocks to watch during ASCO - June 2 at 5:05 PM logoAstraZeneca Appoints Nazneen Rahman As Non-Executive Director - May 31 at 10:34 AM logoExploring the Performance of AstraZeneca’s CVMD Segment in 1Q17 - May 31 at 10:34 AM logoHow AstraZeneca’s Growth Platforms Performed in 1Q17 - May 30 at 12:29 PM logoHow AstraZeneca’s Oncology Segment Performed in 1Q17 - May 30 at 12:29 PM logoShort Interest in AstraZeneca plc (AZN) Decreases By 10.2% - May 30 at 7:02 AM logoChanges in AstraZeneca’s Valuation after Its 1Q17 Earnings - May 29 at 4:07 PM logoAstraZeneca’s Segment-by-Segment Performance in 1Q17 - May 29 at 4:07 PM logoAstraZeneca Delivers New Data on Expanding Portfolio of Cancer Medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - May 26 at 4:08 PM logoAstraZeneca recalls physician sample bottles of heart drug - May 26 at 4:08 PM
News IconBRIEF-AstraZeneca recalls one lot of Brilinta professional sample bottles - May 26 at 2:43 AM logoAstraZeneca Recalls One Lot Of BRILINTA 90mg Professional Sample Bottles - May 26 at 2:43 AM logoAstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot - May 25 at 9:42 PM logoThe Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac - May 24 at 10:54 AM logoPerformance of Merck’s Diabetes Portfolio in 1Q17 - May 24 at 10:54 AM



Astrazeneca PLC (AZN) Chart for Wednesday, June, 28, 2017

This page was last updated on 6/28/2017 by Staff